Clinical and metabolic data to compare the efficacy of myoinositol and metformin in subjects with polycystic ovarian syndrome (PCOS) are limited. Present study was performed to compare myoinositol and metformin in subjects with PCOS.
Introduction
Polycystic ovarian syndrome (PCOS) is a complex condition with multisystem endocrinopathy posing a challenge to female fertility. It is the most common cause of menstrual disturbance, ovarian dysfunction, infertility and metabolic disorders including hyperandrogenism, glucose intolerance and insulin resistance in females of reproductive age. It has significant and diverse clinical implications including reproductive (infertility, hyperandrogenism, hirsutism), metabolic (insulin resistance, impaired glucose tolerance, type 2 diabetes mellitus, adverse cardiovascular risk profiles) and psychological features (increased anxiety, depression and worsened quality of life). 1 As many as 20% of women with infertility problems (including fecundability and early pregnancy loss) have been diagnosed with PCOS. 2 It is often called the most common cause of anovulatory infertility in women. 3 The incidence has increased in recent years due to change in lifestyle and stress.
2
The aetiopathology of PCOS is not clear but most probably a strong genetic cause influenced by gestational environment and lifestyle appears to be the causative factor. Insulin resistance is seen in 50 -70% of PCOS patients. It plays a key role in the clinical development of PCOS in almost all the women both obese and lean. Insulin resistance causes compensatory hypersecretion of insulin particularly in response to glucose, so euglycemia is maintained at the expense of hyperinsulinemia. In addition, myoinositol intake improves reproductive axis functioning in patients with PCOS, reducing the hyperinsulinaemic state. 10 In contrast to metformin, no side effects have been reported following treatment with myoinositol 11 . Myoinositol produces a second messenger, Inositol triphosphate that regulates some hormones such as thyroid -stimulating hormone and follicle-stimulating hormone, and is responsible for glucose uptake 12 , which in turn increases insulin sensitivity. Myoinositol, indeed as a second messenger plays an essential role for the signal pathways of cells. The action of myoinositol would be related to improved insulin sensitivity and a subsequent increased intracellular glucose uptake in particular in PCOS. The aim of this study was to determine the efficacy in the form of pregnancy rates where a combination of myoinositol and folic acid was used in infertile patients with PCOS so as to establish if this molecule can be used as a safer option for the improved pregnancy rate in PCOS. At present data on comparison of myoinositol and metformin on clinical, metabolic and genetic parameters in subjects with PCOS are very small 12 . Therefore this study was carried to compare myoinositol and metformin on clinical and metabolic parameters in these patients.
Patients and Methods
A study during June 2017 to August 2018 was done on patients attending the department of Gynaecology & Obstetrics of Nalanda Medical College, Patna. A total of 100 women with PCOS and infertility were selected and their reports generated according to Rotterdam classification 13 .
Out of 100 patients 50 were recommended Myoinositol 2000 mg thrice a day and Folic acid 200 μg twice a day and continued for at least 3 months. Another 50 patients were treated with Metformin 1500 mg/ day in three divided dosages. The primary outcome of the study was to determine the restoration of ovulatory function and the pregnancy rate following treatment. The secondary outcome was to evaluate the compliance rate and side effects reported in both groups of the patients receiving treatment. In our study the pregnancy outcome was also studied.
Result
The data of 100 women with PCOS were evaluated. Baseline characteristic like age and BMI were almost similar in both groups. In group A, serum fasting insulin level decreased by 51% but not so in group B (38%). There was a significant reduction in Serum testosterone, DHEAS and LH levels and marked improvement in serum estradiol level. 
